Abstract: A steel for a welded structure includes the following composition: by mass %, C at a C content [C] of 0.010 to 0.065%; Si at a Si content [Si] of 0.05 to 0.20%; Mn at a Mn content [Mn] of 1.52 to 2.70%; Ni at a Ni content [Ni] of 0.10% to 1.50%; Ti at a Ti content [Ti] of 0.005 to 0.015%; 0 at an O content [O] of 0.0010 to 0.0045%; N at a N content [N] of 0.002 to 0.006%; Mg at a Mg content [Mg] of 0.0003 to 0.003%; Ca at a Ca content [Ca] of 0.0003 to 0.003%; and the balance composed of Fe and unavoidable impurities. A steel component parameter PCTOD is 0.065% or less, and a steel component hardness parameter CeqH is 0.235% or less.

Abstract: A steel for a welded structure includes the following composition: by mass %, C at a C content [C] of 0.015 to 0.045%; Si at a Si content [Si] of 0.05 to 0.20%; Mn at a Mn content [Mn] of 1.5 to 2.0%; Ni at a Ni content [Ni] of 0.10 to 1.50%; Ti at a Ti content [Ti] of 0.005 to 0.015%; O at an O content [O] of 0.0015 to 0.0035%; and N at a N content [N] of 0.002 to 0.006%, and a balance composed of Fe and unavoidable impurities. In the steel for a welded structure, the P content [P] is limited to 0.008% or less, the S content [S] is limited to 0.005% or less, the Al content [Al] is limited to 0.004% or less, the Nb content [Nb] is limited to 0.005% or less, the Cu content [Cu] is limited to 0.24% or less, the V content [V] is limited to 0.020% or less, and a steel composition parameter PCTOD is 0.065% or less, and a steel composition hardness parameter CeqH is 0.235% or less.

Abstract: The present invention provides a novel isoquinoline derivative which is useful as a pharmaceutical agent having a phosphodiesterase inhibitory activity.

Abstract: Novel heterocyclic biaryl derivatives were disclosed which are useful as pharmaceutical agents and which exhibit a phosphodiesterase-inhibitory action. The heterocyclic biaryl derivatives are represented by the following general formula (1): wherein the Heterocycle 1 and the Heterocycle 2 are directly bonded together.

Abstract: A liquid crystal display device includes: pixel electrodes arranged in columns and rows, each including a reflective electrode region; scanning lines; and signal lines. The device sequentially supplies a scanning signal voltage to one of the scanning lines after another to select one group of pixel electrodes, connected to the same one of the scanning lines, after another, and then supplies display signal voltages to the selected group of pixel electrodes by way of the signal lines, thereby displaying an image thereon. The pixel electrodes are arranged such that the polarity of a voltage to be applied to a liquid crystal layer is inverted for every predetermined number of pixel electrodes in each of the rows and in each of the columns. The display signal voltage to be supplied to each pixel electrode is updated at a frequency of 45 Hz or less.

Abstract: Provided herein are benzoxazinone compounds of formula I and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of serine hydrolase, including neutrophil elastase. In certain embodiments, the compounds and compositions are useful in the prevention, amelioration or treatment of serine hydrolase-mediated diseases.

Abstract: A liquid crystal display device includes: pixel electrodes arranged in columns and rows, each including a reflective electrode region; scanning lines; and signal lines. The device sequentially supplies a scanning signal voltage to one of the scanning lines after another to select one group of pixel electrodes, connected to the same one of the scanning lines, after another, and then supplies display signal voltages to the selected group of pixel electrodes by way of the signal lines, thereby displaying an image thereon. The pixel electrodes are arranged such that the polarity of a voltage to be applied to a liquid crystal layer is inverted for every predetermined number of pixel electrodes in each of the rows and in each of the columns. The display signal voltage to be supplied to each pixel electrode is updated at a frequency of 45 Hz or less.

Abstract: A large-heat-input butt-welded joint of welded structures prepared by butt-welding high-strength steel plates over 50 mm in thickness, having excellent brittle fracture resistance, is characterized by: (a1) the hardness of the weld metal is not more than 110% of the hardness of the base metal or (a2) the hardness of the weld metal is not less than 70% and not more than 110% of the hardness of the base metal, and, as required, (b) the width of the weld metal is not more than 70% of the plate thickness of the base metal, (c) the width of the region affected by welding whose hardness is softened to not more than 95% of the hardness of the non-heat-affected base metal has a width not less than 5 mm, and/or (d) the prior austenite grain size in the heat-affected zone (HAZ) contacting the welding fusion line is not more than 200 ?m.

Abstract: First rubbing is performed on an entire surface of an alignment film provided on a substrate, and then a mask part for masking a first region and a region of an alignment mark is formed on the alignment film by using a resist layer. After performing second rubbing on the alignment film through the mask part, the mask part is removed, and a liquid crystal layer is formed on the alignment film. In this way, the alignment mark is formed as a region having an optical function different from an optical function of a region surrounding the alignment mark. Thus, it is possible to produce a substrate having an alignment mark formed without increasing processing steps at such a position as to contact the liquid crystal layer.

Abstract: It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

Abstract: A novel pyrazolopyridine carboxamide derivative is provided that is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine carboxamide derivative is represented by the following general formula (1): (Example: 2-ethyl-7-methoxypyrazolo[1,5-a]pyridine-4-carboxylic acid (3,5-dichloropyridin-4-yl)amide).

Abstract: To form a welded joint having a sufficiently high fracture toughness value ?c by butting welding high strength steel plates having a yield strength of the 355 MPa class or more and a plate thickness of over 50 mm by electron beam welding, the butt welded joint is made one where the hardness of the weld metal is 110% to 220% of the hardness of the base material and where the width of the weld metal is 20%A or less of the base material plate thickness. More preferably, the amount of O in the weld metal of the welded joint is made 20 ppm or more and the amount of oxides of a grain size of 2.0 ?m or more is made 10/mm2 or less; the weld metal of the welded joint is made to contain Ni in an amount of 1 to 4 mass % and contain it in more than an amount of 0.2 mass % or more of the content of the base material; or, when using as the base material a steel material containing as Ni in an amount of 2.5 mass % or more, making the content of Ni contained in the weld metal of the welded joint, by mass %, over 4% to 8%.

Abstract: The present invention provides high strength steel having unprecedentedly superior CTOD (fracture toughness) properties satisfying not only the CTOD properties of the FL zone at ?60° C., but also the CTOD properties of the ICHAZ zone in small and medium heat input multilayer welding etc. and a method of production of the same. The steel of the present invention is steel superior in CTOD properties of the heat-affected zone containing, by mass %, C: 0.015 to 0.045%, Si: 0.05 to 0.2%, Mn: 1.5 to 2.0%, Cu: 0.25 to 0.5%, Ni: 0.7 to 1.5%, P: 0.008% or less, S: 0.005% or less, Al: 0.004% or less, Ti: 0.005 to 0.015%, Nb: 0.005% or less, 0: 0.0015 to 0.0035%, and N: 0.002 to 0.006%, PCTOD: 0.065 or less, CeqH: 0.235 or less and the balance consisting of Fe and unavoidable impurities.

Abstract: A novel pyrazolopyridine derivative is provided which is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine derivative is represented by the following general formula (1): [wherein R1 is a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like, R2 is an optionally substituted alkyl group having 1 to 6 carbon atoms or the like, R5 and R6 are independently a hydrogen atom or a halogen atom, R13 is a hydrogen atom or a halogen atom, n is 0 or 1, is a single or double bond, R3 is a hydrogen atom, a hydroxyl group, or the like, and R4 is a hydrogen atom, a phenyl group, or the like] or a pharmaceutically acceptable salt thereof, and a hydrate thereof.

Abstract: First rubbing is performed on an entire surface of an alignment film provided on a substrate, and then a mask part for masking a first region and a region of an alignment mark is formed on the alignment film by using a resist layer. After performing second rubbing on the alignment film through the mask part, the mask part is removed. and a liquid crystal layer is formed on the alignment film. In this way, the alignment mark is formed as a region having an optical function different from an optical function of a region surrounding the alignment mark. Thus, it is possible to produce a substrate having an alignment mark formed without increasing processing steps at such a position as to contact the liquid crystal layer.

Abstract: First rubbing is performed on an entire surface of an alignment film (22) provided on a substrate (21), and then a mask part (51a) for masking a first region and a region of an alignment mark is formed on the alignment film (22) by using a resist layer (51). After performing second rubbing on the alignment film (22) through the mask part (51a), the mask part (51a) is removed, and a liquid crystal layer (23) is formed on the alignment film (22). In this way, the alignment mark is formed as a region having an optical function different from an optical function of a region surrounding the alignment mark. Thus, it is possible to produce a substrate (21) having an alignment mark formed without increasing processing steps at such a position as to contact the liquid crystal layer (23).

Abstract: Provided herein are benzoxazinone compounds of formula I and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of serine hydrolase, including neutrophil elastase. In certain embodiments, the compounds and compositions are useful in the prevention, amelioration or treatment of serine hydrolase-mediated diseases.

Abstract: The present invention provides a high-strength thick steel plate having a plate thickness of 50 to 80 mm and a tensile strength of 490 to 570 MPa which is able to realize an excellent HAZ toughness even when welding with a heat input of 20 to 100 kJ/mm is conducted and is characterized by containing, by wt %, 0.03-0.14% of C, 0.30% or less of Si, 0.8-2.0% of Mn, 0.02% or less of P, 0.005% or less of S, 0.8-4.0% of Ni, 0.003-0.040% of Nb, 0.001-0.040% of Al, 0.0010-0.0100% of N, and 0.005-0.030% of Ti, where Ni and Mn satisfy equation [1], and the balance of iron and unavoidable impurities: Ni/Mn?10×Ceq?3 (0.36<Ceq<0.

Abstract: A large-heat-input butt-welded joint of welded structures prepared by butt-welding high-strength steel plates over 50 mm in thickness, having excellent brittle fracture resistance, is characterized by: (a1) the hardness of the weld metal is not more than 110% of the hardness of the base metal or (a2) the hardness of the weld metal is not less than 70% and not more than 110% of the hardness of the base metal, and, as required, (b) the width of the weld metal is not more than 70% of the plate thickness of the base metal, (c) the width of the region affected by welding whose hardness is softened to not more than 95% of the hardness of the non-heat-affected base metal has a width not less than 5 mm, and/or (d) the prior austenite grain size in the heat-affected zone (HAZ) contacting the welding fusion line is not more than 200 ?m.

Abstract: A liquid crystal display device includes: pixel electrodes arranged in columns and rows, each including a reflective electrode region; scanning lines; and signal lines. The device sequentially supplies a scanning signal voltage to one of the scanning lines after another to select one group of pixel electrodes, connected to the same one of the scanning lines, after another, and then supplies display signal voltages to the selected group of pixel electrodes by way of the signal lines, thereby displaying an image thereon. The pixel electrodes are arranged such that the polarity of a voltage to be applied to a liquid crystal layer is inverted for every predetermined number of pixel electrodes in each of the rows and in each of the columns. The display signal voltage to be supplied to each pixel electrode is updated at a frequency of 45 Hz or less.